EGFR TKI combination with immunotherapy in non-small cell lung cancer

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2012 • 11,574 citations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

2015 • 8,603 citations

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

2009 • 7,749 citations

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

2015 • 5,944 citations

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

2015 • 5,526 citations

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

2010 • 5,268 citations

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

2012 • 5,195 citations

Comprehensive molecular profiling of lung adenocarcinoma

2014 • 5,023 citations

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

2009 • 3,957 citations

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

2011 • 3,882 citations

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

2013 • 2,949 citations

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

2013 • 2,195 citations

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

2015 • 1,937 citations

Combining immunotherapy and targeted therapies in cancer treatment

2012 • 1,430 citations

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

2015 • 1,362 citations

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

2013 • 1,135 citations

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

2016 • 1,038 citations

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

2013 • 879 citations

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

2012 • 725 citations

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

2010 • 703 citations

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

2015 • 595 citations

136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

2016 • 228 citations

Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression

2006 • 140 citations

57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

2016 • 109 citations

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).

2014 • 79 citations

Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC

2016 • 69 citations

441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC

2016 • 36 citations

Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).

2015 • 27 citations

Abstract B290: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

2013 • 24 citations